RxSight Investors Urged to Secure Counsel by September 22 Deadline
ByAinvest
Thursday, Sep 18, 2025 9:29 pm ET1min read
RXST--
The class action lawsuit, filed in the United States District Court for the Central District of California, claims that RxSight's management made materially false and misleading statements and failed to disclose significant adverse facts about the company's business, operations, and prospects. The lawsuit alleges that the defendants overstated the demand for RxSight's products and failed to disclose "adoption challenges" and structural issues that led to declines in sales and utilization [1].
Investors who purchased RxSight securities during the Class Period are encouraged to contact Rosen Law Firm to discuss their rights and potential compensation. Rosen Law Firm is known for its expertise in securities class actions and shareholder derivative litigation, with a history of recovering hundreds of millions of dollars for investors [2].
The Rosen Law Firm has achieved notable success in securities class action settlements, including the largest ever settlement against a Chinese company at the time. The firm is ranked among the top in the industry and has been recognized for its leadership in securities class action litigation [2].
Investors are reminded that until a class is certified, they are not represented by counsel unless they retain one. They may select counsel of their choice or remain an absent class member. To join the RxSight class action, investors can visit the Rosen Law Firm's website or contact Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com [2].
Rosen Law Firm reminds RxSight investors to secure counsel before September 22 deadline in securities class action. The lawsuit claims that defendants made false and misleading statements about rising utilization, customer adoption, and field team performance. Investors who purchased RxSight securities between May 7, 2024, and July 8, 2025, may be entitled to compensation through a contingency fee arrangement.
NEW YORK, September 12, 2025 — Rosen Law Firm, a globally recognized investor rights law firm, is urging investors who purchased shares of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024, and July 8, 2025, to secure legal counsel before the September 22, 2025 deadline in a securities class action lawsuit. The lawsuit alleges that the company made false and misleading statements about rising utilization, customer adoption, and field team performance during the specified period [2].The class action lawsuit, filed in the United States District Court for the Central District of California, claims that RxSight's management made materially false and misleading statements and failed to disclose significant adverse facts about the company's business, operations, and prospects. The lawsuit alleges that the defendants overstated the demand for RxSight's products and failed to disclose "adoption challenges" and structural issues that led to declines in sales and utilization [1].
Investors who purchased RxSight securities during the Class Period are encouraged to contact Rosen Law Firm to discuss their rights and potential compensation. Rosen Law Firm is known for its expertise in securities class actions and shareholder derivative litigation, with a history of recovering hundreds of millions of dollars for investors [2].
The Rosen Law Firm has achieved notable success in securities class action settlements, including the largest ever settlement against a Chinese company at the time. The firm is ranked among the top in the industry and has been recognized for its leadership in securities class action litigation [2].
Investors are reminded that until a class is certified, they are not represented by counsel unless they retain one. They may select counsel of their choice or remain an absent class member. To join the RxSight class action, investors can visit the Rosen Law Firm's website or contact Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com [2].

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet